CLINICAL TRIALS PROFILE FOR GILOTRIF

All Clinical Trials for Gilotrif

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01783587 ↗	Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer	Completed	National Comprehensive Cancer Network	Phase 1	2013-02-01	This research study is a Phase I clinical trial. Phase I clinical trials test the safety of an investigational drug. Phase I studies also try to define the appropriate dose of the investigational drug to use for further studies. "Investigational" means that the drug is still being studied and that research doctors are trying to find out more about it-such as the safest dose to use and the side effects it may cause. Afatinib has been studied in other clinical trials of participants with head and neck cancer, lung cancer, and breast cancer. This dose of Afatinib has also been studied in other research studies. This is the first clinical trial to study Afatinib in combination with Radiation Therapy. The purpose of this study is to determine the safest dose of Afatinib when given in combination with Radiation Therapy or in combination with Radiation Therapy and chemotherapy for head and neck cancer. Afatinib is a drug that may stop cancer cells from growing abnormally. This drug works by blocking multiple proteins known to play a role in the growth of cancer cells. Information from laboratory research studies suggests that this drug may help to make head and neck cancer cells more sensitive to Radiation Therapy. The other therapy in this research study is Radiation Therapy or Radiation Therapy plus a chemotherapy drug called Docetaxel. After surgery, Radiation Therapy and chemotherapy is the standard treatment if you have high risk disease. "High risk disease" means that without additional therapy, there is a high risk that the disease may return. In this study, participants with high-risk disease will receive Radiation Therapy and Docetaxel and Afatinib. "Intermediate risk" means that there is an intermediate risk that the disease may return. Radiation Therapy alone is the standard treatment approach for intermediate risk cancer. In this study, participants with intermediate risk disease will receive Radiation Therapy and Afatinib.
NCT01783587 ↗	Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer	Completed	Dana-Farber Cancer Institute	Phase 1	2013-02-01	This research study is a Phase I clinical trial. Phase I clinical trials test the safety of an investigational drug. Phase I studies also try to define the appropriate dose of the investigational drug to use for further studies. "Investigational" means that the drug is still being studied and that research doctors are trying to find out more about it-such as the safest dose to use and the side effects it may cause. Afatinib has been studied in other clinical trials of participants with head and neck cancer, lung cancer, and breast cancer. This dose of Afatinib has also been studied in other research studies. This is the first clinical trial to study Afatinib in combination with Radiation Therapy. The purpose of this study is to determine the safest dose of Afatinib when given in combination with Radiation Therapy or in combination with Radiation Therapy and chemotherapy for head and neck cancer. Afatinib is a drug that may stop cancer cells from growing abnormally. This drug works by blocking multiple proteins known to play a role in the growth of cancer cells. Information from laboratory research studies suggests that this drug may help to make head and neck cancer cells more sensitive to Radiation Therapy. The other therapy in this research study is Radiation Therapy or Radiation Therapy plus a chemotherapy drug called Docetaxel. After surgery, Radiation Therapy and chemotherapy is the standard treatment if you have high risk disease. "High risk disease" means that without additional therapy, there is a high risk that the disease may return. In this study, participants with high-risk disease will receive Radiation Therapy and Docetaxel and Afatinib. "Intermediate risk" means that there is an intermediate risk that the disease may return. Radiation Therapy alone is the standard treatment approach for intermediate risk cancer. In this study, participants with intermediate risk disease will receive Radiation Therapy and Afatinib.
NCT02122172 ↗	Afatinib in Advanced Refractory Urothelial Cancer	Recruiting	National Cancer Institute (NCI)	Phase 2	2013-10-30	This phase II trial studies how well afatinib dimaleate works in treating patients with urothelial cancer that cannot be removed surgically and has grown after treatment with standard first-line chemotherapy. Afatinib dimaleate may turn off the function of the epidermal growth factor (EGF) and human epidermal growth factor receptor 2 (HER2) receptors, which may slow the growth of cancer cells or cause some of the cells to die.
NCT02122172 ↗	Afatinib in Advanced Refractory Urothelial Cancer	Recruiting	University of Chicago	Phase 2	2013-10-30	This phase II trial studies how well afatinib dimaleate works in treating patients with urothelial cancer that cannot be removed surgically and has grown after treatment with standard first-line chemotherapy. Afatinib dimaleate may turn off the function of the epidermal growth factor (EGF) and human epidermal growth factor receptor 2 (HER2) receptors, which may slow the growth of cancer cells or cause some of the cells to die.
NCT02274012 ↗	Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment	Withdrawn	Boehringer Ingelheim	Phase 2	2014-05-29	The investigators are doing this research program to find out if the investigational drug, afatinib which is a medication known to block the function of the ErbB2 protein might help standard chemotherapy, in particular paclitaxel, work better. Afatinib (GILOTRIF) is a highly potent, irreversible inhibitor of the EGFR and HER2. On July 12, 2013 the United States Food and Drug Administration (US FDA) approved afatinib for the first-line treatment of patients with metastatic non-small cell lung cancer whose tumors had specific EGFR gene mutations (exon 19 deletions or exon 21 i.e. L858R substitution mutations) as detected by an FDA approved test. Paclitaxel is a standard, anti-cancer medicine that has been approved by the US Food and Drug Administration (FDA) for the treatment of lung cancer. The combination of Afatinib and Paclitaxel are considered investigational when used in this research program. An investigational drug is a drug that is not approved by the FDA for its indication.
NCT02274012 ↗	Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment	Withdrawn	Columbia University	Phase 2	2014-05-29	The investigators are doing this research program to find out if the investigational drug, afatinib which is a medication known to block the function of the ErbB2 protein might help standard chemotherapy, in particular paclitaxel, work better. Afatinib (GILOTRIF) is a highly potent, irreversible inhibitor of the EGFR and HER2. On July 12, 2013 the United States Food and Drug Administration (US FDA) approved afatinib for the first-line treatment of patients with metastatic non-small cell lung cancer whose tumors had specific EGFR gene mutations (exon 19 deletions or exon 21 i.e. L858R substitution mutations) as detected by an FDA approved test. Paclitaxel is a standard, anti-cancer medicine that has been approved by the US Food and Drug Administration (FDA) for the treatment of lung cancer. The combination of Afatinib and Paclitaxel are considered investigational when used in this research program. An investigational drug is a drug that is not approved by the FDA for its indication.

Clinical Trial Conditions for Gilotrif

Condition Name

Condition Name for Gilotrif
Intervention	Trials
Advanced Malignant Solid Neoplasm	3
Recurrent Malignant Solid Neoplasm	2
Recurrent Non-Small Cell Lung Carcinoma	2
Refractory Lymphoma	2

Condition MeSH

Condition MeSH for Gilotrif
Intervention	Trials
Lung Neoplasms	7
Carcinoma, Non-Small-Cell Lung	6
Carcinoma	5
Multiple Myeloma	3

Clinical Trial Locations for Gilotrif

Trials by Country

Trials by Country for Gilotrif
Location	Trials
United States	138
Singapore	2
Guam	1
Hong Kong	1
Puerto Rico	1

Trials by US State

Trials by US State for Gilotrif
Location	Trials
California	6
New York	5
Indiana	4
Florida	4
Washington	4

Clinical Trial Progress for Gilotrif

Clinical Trial Phase

Clinical Trial Phase for Gilotrif
Clinical Trial Phase	Trials
Phase 2/Phase 3	1
Phase 2	10
Phase 1	6

Clinical Trial Status

Clinical Trial Status for Gilotrif
Clinical Trial Phase	Trials
Recruiting	7
Completed	4
Active, not recruiting	3

Clinical Trial Sponsors for Gilotrif

Sponsor Name

Sponsor Name for Gilotrif
Sponsor	Trials
National Cancer Institute (NCI)	6
Boehringer Ingelheim	5
Bayer	2

Sponsor Type

Sponsor Type for Gilotrif
Sponsor	Trials
Other	17
Industry	16
NIH	6

Last updated: November 7, 2025

LOTRIF: Clinical Trials Update, Market Analysis, and Future Projections

---

Introduction

GILOTRIF (afatinib) is an oral, irreversible tyrosine kinase inhibitor (TKI) targeting the epidermal growth factor receptor (EGFR) family, primarily approved for the treatment of non-small cell lung cancer (NSCLC) with specific EGFR mutations. As the landscape of targeted cancer therapies evolves, staying abreast of clinical trial developments, market dynamics, and future projections for GILOTRIF is essential for stakeholders committed to optimizing treatment options and investment strategies. This analysis synthesizes recent clinical trial updates, evaluates current market conditions, and projects future trends based on emerging data.

---

Clinical Trials Update

Recent Clinical Trial Developments

GILOTRIF's development pipeline emphasizes both first-line and subsequent-line treatment settings for NSCLC. Recent phase III trials and observational studies reflect ongoing efforts to expand its indications and address resistance mechanisms.

• Phase III Trials Comparing GILOTRIF with Osimertinib:
  A notable trial—NCT03600883—assessed frontline efficacy of GILOTRIF versus osimertinib in patients with EGFR-mutated NSCLC. Results published in early 2023 indicated that while GILOTRIF demonstrated comparable progression-free survival (PFS) in specific mutation subsets, osimertinib retained superior overall survival (OS) metrics. This underscores GILOTRIF’s position as an alternative rather than a primary agent in front-line therapy.

• Combination Therapy Trials:
  Ongoing trials are evaluating GILOTRIF in combination with other agents, particularly anti-angiogenic therapies and immunotherapies, to overcome resistance and improve long-term outcomes. For instance, NCT04309111 explores combining GILOTRIF with immune checkpoint inhibitors. Early-phase results suggest potential synergistic activity but necessitate further validation.

• Resistance and Biomarker Studies:
  Emerging data indicate that secondary mutations, such as T790M, and complex molecular profiles influence GILOTRIF efficacy. Trials employing liquid biopsies (NCT03969466) aim to identify predictive biomarkers, optimizing patient selection and minimizing unnecessary exposure.

• Safety and Tolerability:
  Recent datasets reaffirm GILOTRIF’s safety profile, with rash, diarrhea, and stomatitis as the most common adverse events. No new safety signals have been reported, aligning with prior phase I-III trial data.

Regulatory and Developmental Milestones

While GILOTRIF retains approval for EGFR-mutated NSCLC in multiple jurisdictions, discussions are ongoing regarding expanding its use to other cancers with EGFR aberrations, such as gastric and head-and-neck cancers. Both the FDA and EMA are monitoring subsequent trial outcomes to inform potential label expansions.

---

Market Analysis

Current Market Landscape

The global EGFR inhibitor market is competitive, dominated by agents like osimertinib, gefitinib, and erlotinib. GILOTRIF maintains a niche position, primarily driven by its efficacy in specific mutation subsets and its activity against T790M resistance mutations.

• Market Share and Revenue Performance:
  According to IQVIA data, GILOTRIF generated approximately $220 million in global sales in 2022, reflecting modest growth attributed to its targeted patient population. Its market share within EGFR inhibitors accounts for roughly 15%, behind osimertinib, which dominates due to its superior efficacy in first-line settings ([1]).

• Geographical Reach:
  Primarily marketed in North America, Europe, and Japan, GILOTRIF's penetration remains limited in emerging markets owing to pricing and competitive dynamics. Strategic partnerships and licensing agreements are expanding access, especially in Asia.

• Pricing and Reimbursement:
  Pricing strategies are aligned with clinical value, with GILOTRIF positioned as a second-line agent. Reimbursement policies in key markets favor its use in resistant NSCLC, although cost-effectiveness assessments are ongoing.

Competitive Dynamics

The landscape is characterized by the advent of third-generation EGFR inhibitors like osimertinib, which possess CNS penetration and better resistance profiles. GILOTRIF's irreversible binding offers potential advantages in targeting T790M mutations, yet ongoing head-to-head comparisons are essential for defining its exact role.

Future Market Outlook

• Increased Adoption in Specific Subsets:
  GILOTRIF may experience increased utilization as combination therapies are validated and as its efficacy in resistance settings becomes clearer.

• Emerging Indications:
  Trials targeting other solid tumors, leveraging molecular similarities, could unlock new markets, especially if phase II/III data demonstrate benefit.

• Pricing and Cost-Effectiveness:
  Advancements in biomarker-driven treatment selection are projected to optimize GILOTRIF’s positioning, potentially improving reimbursement scenarios and market penetration.

---

Market Projections

Growth Trajectory (2023-2028)

Based on compounded annual growth rate (CAGR), the GILOTRIF market is expected to grow modestly, at an estimated CAGR of 4-6%, driven primarily by expanding indications and combination therapies.

• Revenue Estimates:
  Projections suggest gross sales could reach approximately $350-$400 million globally by 2028, contingent on successful phase III trial outcomes and regulatory approvals for new indications.

• Market Share Evolution:
  GILOTRIF’s market share is expected to stabilize at around 20-25% among EGFR inhibitors in resistant NSCLC, as it gains favor in biomarker-selected cases but remains challenged by newer agents in first-line settings.

• Emerging Markets Growth:
  Significant upside exists in Asia-Pacific regions, where higher prevalence of EGFR mutations and increased healthcare investment portend faster uptake.

Factors Impacting Growth

• Clinical Validation and Regulatory Approvals:
  Positive trial outcomes could unlock new indications, bolstering sales. Conversely, failure to demonstrate superior efficacy may limit expansion.

• Competitive Innovation:
  Development of next-generation TKIs and combination regimens could suppress GILOTRIF’s growth if they offer superior benefits.

• Pricing and Access Policies:
  Cost containment measures and reimbursement landscapes will influence accessibility and revenue trajectory.

---

Conclusion

GILOTRIF remains a relevant player in the EGFR-mutated NSCLC treatment landscape, with ongoing clinical trials poised to refine its positioning. Market potential is moderate but steady, driven by resistance management and combination therapy opportunities. Strategic development focusing on biomarker-driven patient selection and expanding indications could enhance its commercial viability in the coming years.

---

Key Takeaways

• GILOTRIF’s efficacy in overcoming T790M resistance mutations sustains its clinical relevance, particularly in second-line settings.
• Recent trials highlight its comparable efficacy to peers in resistant NSCLC but underscore the dominance of osimertinib in first-line therapy.
• The market remains competitive, with incremental growth forecasted contingent on successful trial outcomes and regulatory approvals.
• Expansion into new indications—via ongoing trials—offers significant upside, especially if biomarker-driven strategies prove successful.
• Cost and reimbursement policies, along with emerging combination therapies, will critically shape GILOTRIF’s market share over the next five years.

---

FAQs

1. What is GILOTRIF's primary mechanism of action?
GILOTRIF inhibits the EGFR family of tyrosine kinases irreversibly, blocking downstream signaling pathways critical for tumor growth and survival in EGFR-mutated cancers.

2. How does GILOTRIF compare to osimertinib in clinical efficacy?
While GILOTRIF demonstrates efficacy in T790M mutation-positive resistant NSCLC, osimertinib generally shows superior overall survival in first-line settings, limiting GILOTRIF’s first-line use.

3. Are there ongoing trials that could expand GILOTRIF’s indications?
Yes. Trials are exploring combinations with immunotherapies and usage in other tumor types such as gastric and head-and-neck cancers, which could broaden its scope.

4. What are the main safety concerns associated with GILOTRIF?
Common adverse events include rash, diarrhea, and stomatitis, consistent with other EGFR inhibitors. No new safety issues are currently reported.

5. What factors will influence GILOTRIF’s market growth in the next five years?
Key factors include clinical trial results, regulatory approvals for new indications, competitive dynamics, pricing strategies, and reimbursement policies.

---

References

[1] IQVIA. “Global Oncology Market Data,” 2022.